Compare ATLC & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLC | DMRA |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2009 | 2020 |
| Metric | ATLC | DMRA |
|---|---|---|
| Price | $96.09 | $30.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $90.00 | $43.00 |
| AVG Volume (30 Days) | 147.3K | ★ 363.9K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.95 | ★ 121.48 |
| EPS | ★ 4.74 | N/A |
| Revenue | ★ $1,968,399,000.00 | N/A |
| Revenue This Year | $477.21 | N/A |
| Revenue Next Year | $10.42 | N/A |
| P/E Ratio | $19.76 | ★ N/A |
| Revenue Growth | ★ 50.09 | N/A |
| 52 Week Low | $47.50 | $16.50 |
| 52 Week High | $114.34 | $34.89 |
| Indicator | ATLC | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 54.05 |
| Support Level | $91.51 | $28.16 |
| Resistance Level | $113.47 | $31.77 |
| Average True Range (ATR) | 5.91 | 1.69 |
| MACD | -1.11 | -0.06 |
| Stochastic Oscillator | 19.25 | 46.29 |
Atlanticus Holdings Corp is a financial technology company powering more inclusive financial solutions for Everyday Americans. It provides technology and other support services to lenders who offer an array of financial products and services to consumers. The company's products and services are reported through two reportable segments. Credit as a Service (CaaS) offers products including private label credit cards using the Fortiva and Curae brand names as well as merchant-associated brands and Auto Finance provides purchase and/or service loans secured by automobiles from or for, and also provides floor-plan financing for, a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here used car business.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.